PPD Launches new Global Biostatistics Technology Infrastructure
News Dec 03, 2009
PPD, Inc. has announced it has launched a new global information technology infrastructure for analysis and reporting of clinical trial data.
The biostatistics technology infrastructure (BTI) is a centralized computing platform that enhances the company’s ability to deliver secure, quality reporting and data analysis to meet client timelines.
The virtual server environment allows PPD to deploy global teams of biostatisticians and programmers to projects on a single platform. The analysis processing environments are located in the same data centers as PPD's clinical data management systems, eliminating the need to move large quantities of data between file servers. Operating on this unified platform reduces bandwidth utilization, increases employee productivity and creates significant time savings.
“This new environment allows our employees around the world to work together, accessing the same data,” said Susan Atkinson, senior vice president, global biometrics and technical operations for PPD. "Our investment in a global, innovative solution decreases our computer processing time and enhances our data security, giving us the ability to deliver more efficiently for our clients.”
In addition, the BTI features a number of best practice global solutions such as code development, version control, output configuration, validation and delivery of production output. PPD has installed the BTI at its U.S. locations in Austin, Texas, and Research Triangle Park, N.C., as well as at its European headquarters in Cambridge, U.K.
PPD employs approximately 300 biostatisticians and programmers worldwide who provide study design, planning and reporting expertise across all phases of drug development. The company’s reporting services range from Phase I trials through regulatory submission and post approval and include full support of the Clinical Data Interchange Standards Consortium data standards.
Huntsman Cancer Institute Joins National Clinical Trial Targeting AMLNews
Huntsman Cancer Institute (HCI) at the University of Utah (U of U) has been selected to participate in the Beat AML Master Trial, an innovative clinical trial sponsored by The Leukemia & Lymphoma Society (LLS). The clinical trial is testing several new targeted therapies for the treatment of patients with acute myeloid leukemia (AML). HCI is the only facility in the Mountain West offering this trial to AML patients.READ MORE